![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NEUROBIOLOGICAL TO SELL BRAIN TUMOR COMPOUND RIGHTS FOR $33 MLN
NEUROBIOLOGICAL TO SELL BRAIN TUMOR COMPOUND RIGHTS FOR $33 MLN
Neurobiological Technologies Inc. (NTII.O: Quote, Profile, Research) on Tuesday said it agreed to sell worldwide rights in Xerecept, a phase III clinical compound for the treatment for swelling associated with brain tumors, to Celtic Pharma Holdings L.P. for $33 million. Under the terms of the agreement, Neurobiological will receive $20 million upon closing and an additional $13 million in subsequent non-contingent payments, the companies said in separate news releases.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct